Abstract
Background and Aims
The Inflammatory Bowel Diseases (IBDs), Crohn’s Disease (CD) and Ulcerative Colitis (UC), are gastrointestinal autoimmune disorders with many Extraintestinal Manifestations (EIMs). Previously reported incidences of EIMs in IBD patients have ranged from 10% to 50%. The large variation in occurrence of EIMs has been linked to genetic predisposition. Correlations between individual EIMs are unclear. Therefore, we aim to estimate the incidence of EIMs in a Middle Eastern cohort of patients with IBD and examine possible relationships with EIMs.
Patients and Methods
We conducted a retrospective study involving all patients included in the King Abdulaziz University IBD information system registry between 2013 and 2018. Data on demographics, disease characteristics, and EIMs were extracted and analyzed using descriptive statistics: the standard Student’s t-test and chi-squared test. Logistic regression analysis was used to examine associations using STATA software version 11.2 (StataCorp, TX, USA).
Results
We reviewed the electronic medical files of 284 patients with confirmed IBD, of which 158 (55.6%) were females, the mean age was 27.8 (±15) years; 146 (51.4%) patients had CD and 138 (48.6%) UC. The overall incidence risk of EIMs was 138 (52.3%) over a mean duration of follow up of 7.3 (±3.9) years. The most common EIM was arthritis (33%), followed by aphthous ulcers (16%). Pyoderma gangrenosum occurred in 8% of patients and appeared to be specific for CD patients (p = 0.002), whereas Primary Sclerosing Cholangitis (PSC) was more specific for UC (p = 0.001). Certain EIMs appeared to occur together such as arthritis with PSC (p = 0.001). Regression analysis identified disease type (in favor of UC; odds ratio = 0.50, p = 0.03) and age at the time of diagnosis (odds ratio = 1.04, p = 0.001) as the only significant predictors of EIMs.
Conclusion
Our results demonstrate that more than half of IBD patients have at least one EIM. Contrary to what has often been reported, we found that EIMs occur more commonly in UC than CD. A multidisciplinary assessment is recommended as part of IBD management to improve overall health outcomes.
Article PDF
Avoid common mistakes on your manuscript.
References
Danese S, Sans M, Fiocchi C. Inflammatory bowel disease: the role of environmental factors. Autoimmun Rev 2004;3;394–400.
Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142;46.e42–54.e42;quiz e30.
Isene R, Munkholm P, Stockbrügger R, Odes S, Bernklev T, Moum B. M1126 extraintestinal manifestations of inflammatory bowel disease and their impact on quality of life: results from the European Collaborative Study of Inflammatory Bowel Disease (EC-IBD). Gastroenterology 2009;136;A–355.
Danese S, Semeraro S, Papa A, Roberto I, Scaldaferri F, Fedeli G, et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol 2005;11;7227–36.
Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001;96;1116–22.
Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Harmsen WS, Zinsmeister AR, et al. Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study. Inflamm Bowel Dis 2004;10;207–14.
Mendoza JL, Lana R, Taxonera C, Alba C, Izquierdo S, Díaz-Rubio M. [Extraintestinal manifestations in inflammatory bowel disease: differences between Crohn’s disease and ulcerative colitis]. Med Clin (Barc) 2005;125;297–300 [Article in Spanish].
Rankin GB, Watts HD, Melnyk CS, Kelley ML. National Cooperative Crohn’s Disease Study: extraintestinal manifestations and perianal complications. Gastroenterology 1979;77;914–20.
Su CG, Judge TA, Lichtenstein GR. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Clin North Am 2002;31;307–27.
Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn’s disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 1976;55;401–12.
Farmer RG, Hawk WA, Turnbull RB. Clinical patterns in Crohn’s disease: a statistical study of 615 cases. Gastroenterology 1975;68; 627–35.
Wang YF, Ouyang Q, Hu RW. Progression of inflammatory bowel disease in China. J Dig Dis 2010;11;76–82.
Wang YF, Zhang H, Ouyang Q. Clinical manifestations of inflammatory bowel disease: east and west differences. J Dig Dis 2007;8;121–7.
Larsen S, Bendtzen K, Nielsen OH. Extraintestinal manifestations of inflammatory bowel disease: epidemiology, diagnosis, and management. Ann Med 2010;42;97–114.
Juillerat P, Mottet C, Pittet V, Froehlich F, Felley C, Gonvers JJ, et al. Extraintestinal manifestations of Crohn’s disease. Digestion 2007;76;141–8.
Bandyopadhyay D, Bandyopadhyay S, Ghosh P, De A, Bhattacharya A, Dhali GK, et al. Extraintestinal manifestations in inflammatory bowel disease: prevalence and predictors in Indian patients. Indian J Gastroenterol 2015;34;387–94.
Lakatos L, Pandur T, David G, Balogh Z, Kuronya P, Tollas A, et al. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World J Gastroenterol 2003;9;2300–7.
Kethu SR. Extraintestinal manifestations of inflammatory bowel diseases. J Clin Gastroenterol 2006;40;467–75.
Alharbi OR, Azzam NA, Almalki AS, Almadi MA, Alswat KA, Sadaf N, et al. Clinical epidemiology of ulcerative colitis in Arabs based on the Montréal classification. World J Gastroenterol 2014;20;17525–31.
Aljebreen AM, Alharbi OR, Azzam NA, Almalki AS, Alswat KA, Almadi MA. Clinical epidemiology and phenotypic characteristics of Crohn’s disease in the central region of Saudi Arabia. Saudi J Gastroenterol 2014;20;162–9.
Alreheili KM, Alsaleem KA, Almehaidib AI. Natural history and outcome of inflammatory bowel diseases in children in Saudi Arabia: a single-center experience. Saudi J Gastroenterol 2018;24;171–6.
Vavricka SR, Brun L, Ballabeni P, Pittet V, Vavricka BMP, Zeitz J, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. The Am J Gastroenterol 2011;106;110–19.
Singh B, Kedia S, Konijeti G, Mouli VP, Dhingra R, Kurrey L, et al. Extraintestinal manifestations of inflammatory bowel disease and intestinal tuberculosis: frequency and relation with disease phenotype. Indian J Gastroenterol 2015;34;43–50.
Meuwissen SG, Crusius BJ, Peña SA, Dekker-Saeys AJ, Dijkmans BA. Spondyloarthropathy and idiopathic inflammatory bowel diseases. Inflamm Bowel Dis 1997;3;25–37.
Veloso FT. Inflammatory extraintestinal manifestations associated with IBD. In: Monteiro E, Tavarela Veloso F, editors. Inflammatory bowel diseases: new insight into mechanisms of inflammation and challenges in diagnosis and treatment. Lancaster: Kluwer Academic Publishers; 1995, pp. 232–6.
Herfarth H, Obermeier F, Andus T, Rogler G, Nikolaus S, Kuehbacher T, et al. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn’s disease. Am J Gastroenterol 2002;97;2688–90.
Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2015;21;1982–92.
Scarpa R, D’Arienzo A, Del Puente A, Panarese A, di Girolamo C, Larizza G, et al. Reverse correlation between extent of colon involvement and number of affected joints in patients with ulcerative colitis and arthritis. Am J Gastroenterol 1990;85;331–2.
Caillat-Zucman S. Molecular mechanisms of HLA association with autoimmune diseases. Tissue Antigens 2009;73;1–8.
Turkcapar N, Toruner M, Soykan I, Aydintug OT, Cetinkaya H, Duzgun N, et al. The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease. Rheumatol Int 2006;26;663–8.
Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease: a prospective study of 792 patients. J Clin Gastroenterol 1996;23;29–34.
Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 2006;12;4819–31.
Ślebioda Z, Szponar E, Kowalska A. Etiopathogenesis of recurrent aphthous stomatitis and the role of immunologic aspects: literature review. Arch Immunol Ther Exp (Warsz) 2014;62;205–15.
Yüksel İ, Başar Ö, Ataseven H, Ertuğrul İ, Arhan M, İbiş M, et al. Mucocutaneous manifestations in inflammatory bowel disease. Inflamm Bowel Dis 2009;15;546–50.
Campbell S, Cripps S, Jewell DP. Therapy Insight: pyoderma gangrenosum—old disease, new management. Nat Clin Pract Gastroenterol Hepatol 2005;2;587–94.
Florin TH, Pandeya N, Radford-Smith GL. Epidemiology of appendicectomy in primary sclerosing cholangitis and ulcerative colitis: its influence on the clinical behaviour of these diseases. Gut 2004;53;973–9.
Author information
Authors and Affiliations
Corresponding author
Additional information
Data availability statement: The data that support the findings of this study are available from the corresponding author (MM), upon reasonable request.
Rights and permissions
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
About this article
Cite this article
Adam, H., Alqassas, M., Saadah, O.I. et al. Extraintestinal Manifestations of Inflammatory Bowel Disease in Middle Eastern Patients. J Epidemiol Glob Health 10, 298–303 (2020). https://doi.org/10.2991/jegh.k.200330.001
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2991/jegh.k.200330.001